Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 9, 2009
Last updated: May 14, 2011
Last verified: May 2011

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research trial is studying matrix metalloproteinases after surgery or radiofrequency ablation in patients with liver metastases from colorectal cancer.

Condition Intervention
Colorectal Cancer
Metastatic Cancer
Other: laboratory biomarker analysis
Procedure: cryosurgery
Procedure: radiofrequency ablation
Procedure: therapeutic conventional surgery

Study Type: Observational
Official Title: Study of Diagnostic Tests Studying Kinetic Variation of Serum Matrix Metalloproteases After Surgical Treatment and/or Destruction by Radiofrequency in Patients With Hepatic Metastases From Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP)

Secondary Outcome Measures:
  • Predictive value of postoperative risk of recurrence
  • Correlation of risk of recurrence with surgical technique
  • Elevated serum levels of MMP vs carcinoembryonic antigen as a marker of hepatic or extrahepatic recurrence
  • Correlation of postoperative serum HGF/SF with plasma levels in MMPs

Estimated Enrollment: 75
Study Start Date: September 2003
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:



  • Describe the kinetics of postoperative changes of serum matrix metalloproteinases (MMP) (MMP-1, MMP-2, MMP-7, MMP-9) and their inhibitors (TIMP) (TIMP-1, TIMP-2) as a function of surgical technique.


  • Determine the predictive value of postoperative risk of recurrence.
  • Correlate the risk of recurrence with surgical technique.
  • Determine whether elevated serum levels of MMP are a better marker than the carcinoembryonic antigen of hepatic or extrahepatic recurrence.
  • Determine whether the postoperative serum of HGF/SF is correlated to changes in plasma levels of MMPs.

OUTLINE: Blood samples are collected periodically before and after treatment to analyze for metalloproteinases and their inhibitors.

After completion of study treatment, patients are followed at day 45 and then every 3 months for 2 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Meets 1 of the following criteria:

    • Patients with histologically confirmed adenocarcinoma of the colon or rectum and liver metastases

      • Must have undergone prior complete resection of the tumor more than 3 months ago
      • Liver metastases must be resectable or accessible for radiofrequency ablation
    • Patients undergoing cryosurgery of the digestive tract for a reason other than cancer or infection (control)


  • No other neoplastic disease that is measurable or being treated other than colorectal cancer
  • No heart failure or severe respiratory disease
  • No uncontrolled infection or other severe disease


  • See Disease Characteristics
  • No participation in another study involving new drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00899210

Sponsors and Collaborators
University Hospital, Grenoble
Study Chair: Christine Rebischung University Hospital, Grenoble
  More Information Identifier: NCT00899210     History of Changes
Other Study ID Numbers: CDR0000574192
Study First Received: May 9, 2009
Last Updated: May 14, 2011

Keywords provided by National Cancer Institute (NCI):
liver metastases
adenocarcinoma of the colon
stage IV colon cancer
adenocarcinoma of the rectum
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Neoplasm Metastasis
Colorectal Neoplasms
Neoplastic Processes
Pathologic Processes
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on April 25, 2017